Abattis Names Jaouad Fichtali As Chief Technology Officer

Vancouver, BC / ACCESSWIRE / November 17, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") ATTBF ATT, a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that Jaouad Fichtali will assume the role of Chief Technology Officer of Abattis effective November 17, 2014.

Mr. Fichtali joins the team as a leader in his field in taking biotechnology from concept to sustainable commercialization. He is a global Biotech executive whose background includes successful commercialization and improvements to renewable bio-based materials, food ingredients and health and nutrition products. He has successfully driven multimillion-dollar growth. Mr. Fichtali takes ideas from inception to profitable commercialization by creating innovative solutions. He is known as a strategic leader with deep scientific expertise, and comprehensive business acumen.

Mr.Fichtali has a long-standing business relationship working with Abattis Director Tim Fealy. The Company is pleased to finally have both Mr. Fichtali and Mr. Fealy on the Abattis team.

In announcing the appointment of Jaouad Fichtali, Mike Withrow, Chairman of the Board, stated "Jaouad is a welcome addition to the Abattis group of Companies. His expertise in extraction is hard to find anywhere and we are looking forward to his role as CTO and his input on North American Bioextract."

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD

"Mike Withrow"
Michael Withrow, President & CEO

For further information, contact the Company's Investor Relations, Saf Dhillon at (604) 336.0881 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.

SOURCE: Abattis Bioceuticals Corp.